With COVID-19 a residual but still very real issue globally, Novo Holdings asked the big diagnostics question at a recent high-level roundtable: How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? The CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.

During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.